🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

60 results for “Tecentriq” Clear

  1. Tecentriq 1 200 mg concentrate for solution for infusion, OXALIPLATINE HOSPIRA 5 mg/ml, solution à diluer pour perfusion, Avastin 25 mg/ml concentrate for solution for infusion., CAPECITABINE VIATRIS 500 mg, comprimé pelliculé

    CERO THERAPEUTICS HOLDINGS, INC.

    microsatellite stable (MSS) colorectal cancer with liver-dominant metastasis

    phase 2 small molecule active

    1 trial

  2. Tecentriq 1 200 mg concentrate for solution for infusion, Pulmocis 2 mg trousse pour préparation radiopharmaceutique, Avastin 25 mg/ml concentrate for solution for infusion.

    The George Institute

    Non resectable Hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  3. Tecentriq 1 200 mg concentrate for solution for infusion, Tiragolumab

    Disc Medicine

    Squamous cell carcinoma of the anal canal

    phase 2 small molecule active

    1 trial

  4. Tecentriq 1,200 mg concentrate for solution for infusion, EXL01, IMFINZI 50 mg/mL concentrate for solution for infusion., Avastin 25 mg/ml concentrate for solution for infusion., Tecentriq 840 mg concentrate for solution for infusion, IMJUDO 20 mg/ml concentrate for solution for infusion., Avastin 25 mg/ml concentrate for solution for infusion.

    Ningbo Cancer Hospital

    Hepatocellular carcinoma

    phase 2 small molecule active

    1 trial

  5. Tecentriq 840 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  6. Tecentriq 840 mg concentrate for solution for infusion, Tiragolumab

    Hoffmann-La Roche

    Solid tumors

    phase 2 small molecule active

    1 trial

  7. Tiragolumab placebo, Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Squamous cell carcinoma of the head and neck (SCCHN)

    phase 2 small molecule active

    1 trial

  8. Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion

    Disc Medicine

    HNSCC, metastatic deficient mismatch repair (dMMR)/MSI-high (MSI-H) tumors, irresectable or metastatic melanoma, locally advanced or metastatic solid tumor

    phase 2 small molecule active

    1 trial

  9. Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion, RO7247669

    Hoffmann-La Roche

    Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

    phase 2 small molecule active

    1 trial

  10. ZENGAC “500 mg Polvere per soluzione per infusione e per uso orale”, Plenvu, polvere per soluzione orale, SELG ESSE polvere per soluzione orale, Avastin 25 mg/ml concentrate for solution for infusion., Tecentriq 1 200 mg concentrate for solution for infusion, Vancomicina Mylan 500 mg polvere per soluzione per infusione

    Istituto Gentili S.r.l.

    unresectable hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  11. pelareorep, Tecentriq 840 mg concentrate for solution for infusion

    ONCOLYTICS BIOTECH INC

    Patients with advanced or metastatic gastrointestinal (GI) tumors.

    phase 2 small molecule active

    1 trial

  12. Tiragolumab, CISPLATIN , Tecentriq 1 200 mg concentrate for solution for infusion, GEMCITABINE

    Hoffmann-La Roche

    Urothelial carcinoma (UC)

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources